AR071937A1 - Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa - Google Patents
Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfaInfo
- Publication number
- AR071937A1 AR071937A1 ARP090101912A ARP090101912A AR071937A1 AR 071937 A1 AR071937 A1 AR 071937A1 AR P090101912 A ARP090101912 A AR P090101912A AR P090101912 A ARP090101912 A AR P090101912A AR 071937 A1 AR071937 A1 AR 071937A1
- Authority
- AR
- Argentina
- Prior art keywords
- polyoxyethylene
- oxyethylene
- poly
- aqueous solution
- pluronic
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- -1 polyethylene Polymers 0.000 abstract 20
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 8
- 239000007864 aqueous solution Substances 0.000 abstract 6
- 239000004359 castor oil Substances 0.000 abstract 5
- 125000006353 oxyethylene group Chemical group 0.000 abstract 5
- 235000019438 castor oil Nutrition 0.000 abstract 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 4
- 229920001451 polypropylene glycol Polymers 0.000 abstract 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 abstract 2
- 150000002194 fatty esters Chemical class 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 abstract 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 abstract 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 abstract 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 abstract 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 abstract 1
- 229940058015 1,3-butylene glycol Drugs 0.000 abstract 1
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 abstract 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 abstract 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 abstract 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- YYVFXSYQSOZCOQ-UHFFFAOYSA-N Oxyquinoline sulfate Chemical compound [O-]S([O-])(=O)=O.C1=C[NH+]=C2C(O)=CC=CC2=C1.C1=C[NH+]=C2C(O)=CC=CC2=C1 YYVFXSYQSOZCOQ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002415 Pluronic P-123 Polymers 0.000 abstract 1
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 229920001219 Polysorbate 40 Polymers 0.000 abstract 1
- 229920001214 Polysorbate 60 Polymers 0.000 abstract 1
- 229920002642 Polysorbate 65 Polymers 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 abstract 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 abstract 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 abstract 1
- 239000004147 Sorbitan trioleate Substances 0.000 abstract 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 abstract 1
- 229960002470 bimatoprost Drugs 0.000 abstract 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 abstract 1
- 235000019437 butane-1,3-diol Nutrition 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004106 citric acid Drugs 0.000 abstract 1
- 229960001305 cysteine hydrochloride Drugs 0.000 abstract 1
- VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 abstract 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 abstract 1
- 229960001160 latanoprost Drugs 0.000 abstract 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- 229960001257 oxyquinoline sulfate Drugs 0.000 abstract 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 abstract 1
- DOIRQSBPFJWKBE-UHFFFAOYSA-N phthalic acid di-n-butyl ester Natural products CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 229920001992 poloxamer 407 Polymers 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 abstract 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 abstract 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 abstract 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 abstract 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 abstract 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 abstract 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 abstract 1
- 229940101027 polysorbate 40 Drugs 0.000 abstract 1
- 229940113124 polysorbate 60 Drugs 0.000 abstract 1
- 229940099511 polysorbate 65 Drugs 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229960003975 potassium Drugs 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000000473 propyl gallate Substances 0.000 abstract 1
- 235000010388 propyl gallate Nutrition 0.000 abstract 1
- 229940075579 propyl gallate Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 abstract 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 abstract 1
- 235000010262 sodium metabisulphite Nutrition 0.000 abstract 1
- 235000010288 sodium nitrite Nutrition 0.000 abstract 1
- 229960000819 sodium nitrite Drugs 0.000 abstract 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 abstract 1
- 229940046307 sodium thioglycolate Drugs 0.000 abstract 1
- 229940035044 sorbitan monolaurate Drugs 0.000 abstract 1
- 239000001593 sorbitan monooleate Substances 0.000 abstract 1
- 235000011069 sorbitan monooleate Nutrition 0.000 abstract 1
- 229940035049 sorbitan monooleate Drugs 0.000 abstract 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 abstract 1
- 239000001570 sorbitan monopalmitate Substances 0.000 abstract 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 abstract 1
- 239000001587 sorbitan monostearate Substances 0.000 abstract 1
- 235000011076 sorbitan monostearate Nutrition 0.000 abstract 1
- 229940035048 sorbitan monostearate Drugs 0.000 abstract 1
- 235000019337 sorbitan trioleate Nutrition 0.000 abstract 1
- 229960000391 sorbitan trioleate Drugs 0.000 abstract 1
- 239000001589 sorbitan tristearate Substances 0.000 abstract 1
- 235000011078 sorbitan tristearate Nutrition 0.000 abstract 1
- 229960004129 sorbitan tristearate Drugs 0.000 abstract 1
- 239000008347 soybean phospholipid Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 229960004458 tafluprost Drugs 0.000 abstract 1
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 abstract 1
- 229960004605 timolol Drugs 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 229940042585 tocopherol acetate Drugs 0.000 abstract 1
- 229960002368 travoprost Drugs 0.000 abstract 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 abstract 1
- 229950008081 unoprostone isopropyl Drugs 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08397513A EP2127638A1 (en) | 2008-05-30 | 2008-05-30 | Method and composition for treating ocular hypertension and glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071937A1 true AR071937A1 (es) | 2010-07-28 |
Family
ID=39940592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090101912A AR071937A1 (es) | 2008-05-30 | 2009-05-28 | Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa |
| ARP180103181A AR120961A2 (es) | 2008-05-30 | 2018-11-01 | Método y composición para tratar hipertensión ocular y glaucoma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103181A AR120961A2 (es) | 2008-05-30 | 2018-11-01 | Método y composición para tratar hipertensión ocular y glaucoma |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9999593B2 (enExample) |
| EP (8) | EP2127638A1 (enExample) |
| JP (9) | JP2011521943A (enExample) |
| KR (5) | KR101650006B1 (enExample) |
| CN (1) | CN102083413B (enExample) |
| AR (2) | AR071937A1 (enExample) |
| AU (1) | AU2009252210C1 (enExample) |
| BR (1) | BRPI0913109B8 (enExample) |
| CA (2) | CA2724194C (enExample) |
| CY (2) | CY1115565T1 (enExample) |
| DK (4) | DK3714877T3 (enExample) |
| EA (1) | EA023661B1 (enExample) |
| ES (6) | ES2907982T3 (enExample) |
| GE (1) | GEP20156220B (enExample) |
| HR (4) | HRP20220361T1 (enExample) |
| HU (3) | HUE049923T2 (enExample) |
| JO (1) | JO3039B1 (enExample) |
| LT (3) | LT3714877T (enExample) |
| MX (1) | MX2010012987A (enExample) |
| MY (1) | MY159463A (enExample) |
| PL (4) | PL3205334T3 (enExample) |
| PT (4) | PT2772249T (enExample) |
| SG (1) | SG191628A1 (enExample) |
| SI (4) | SI3205334T1 (enExample) |
| TW (1) | TWI432202B (enExample) |
| UA (1) | UA102257C2 (enExample) |
| WO (1) | WO2009145356A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI544927B (zh) | 2008-03-17 | 2016-08-11 | 愛爾康研究有限公司 | 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物 |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| US20110136872A1 (en) * | 2009-12-09 | 2011-06-09 | Burk Robert M | Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof |
| JP5681472B2 (ja) * | 2009-12-28 | 2015-03-11 | ロート製薬株式会社 | 眼科用組成物 |
| FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| US10154923B2 (en) * | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
| CA2806973A1 (en) * | 2010-07-29 | 2012-02-02 | Allergan, Inc. | Preservative free bimatoprost solutions |
| US9061034B2 (en) * | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| EP2598118B1 (en) * | 2010-07-29 | 2018-09-05 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| WO2012038469A2 (en) * | 2010-09-21 | 2012-03-29 | S&V Technologies Ag | Cosmetic composition |
| EP2452669A1 (en) * | 2010-10-29 | 2012-05-16 | Omnivision GmbH | Ophthalmic composition |
| EP2696876A4 (en) * | 2011-04-12 | 2014-09-03 | R Tech Ueno Ltd | AQUEOUS OPHTHALMIC COMPOSITION |
| CN102716074B (zh) * | 2012-06-28 | 2013-10-16 | 武汉武药科技有限公司 | 一种贝美前列素滴眼剂及其制备方法 |
| US8980839B2 (en) * | 2012-08-24 | 2015-03-17 | Ocular Technologies Sarl | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
| US9956195B2 (en) | 2014-01-07 | 2018-05-01 | Nanyang Technological University | Stable liposomal formulations for ocular drug delivery |
| CA2935957C (en) | 2014-01-10 | 2023-01-03 | Manistee Partners Llc | Treatment of migraines using topical administration of prostaglandin f2alpha analogs |
| CN104766952B (zh) * | 2015-04-21 | 2017-01-25 | 武汉凯迪工程技术研究总院有限公司 | 利用生物质气化炉滤渣制备锂离子电池负极材料的方法 |
| ES2747302T3 (es) | 2015-06-09 | 2020-03-10 | Medproject Pharma Entw Und Vertriebsgesellschaft Mbh | Gel oftálmico de bimatoprost aplicable en gotas |
| US10105371B2 (en) * | 2015-10-09 | 2018-10-23 | Tamara Vrabec | Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject |
| US20180325854A1 (en) * | 2015-11-06 | 2018-11-15 | Accuitis Pharmaceuticals, Inc. | Use of proteasome inhibitors to treat ocular disorders |
| WO2017083167A1 (en) | 2015-11-10 | 2017-05-18 | Ocular Technologies Sarl | Topical formulations and uses thereof |
| NZ785158A (en) | 2016-02-29 | 2025-03-28 | Sun Pharmaceutical Ind Ltd | Topical cyclosporine-containing formulations and uses thereof |
| GR1009040B (el) * | 2016-04-19 | 2017-05-19 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου |
| WO2018033854A1 (en) * | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
| KR101770324B1 (ko) * | 2016-11-09 | 2017-08-22 | 주식회사태준제약 | 안압 강하용 점안 조성물 |
| JP2020059652A (ja) * | 2016-12-26 | 2020-04-16 | 参天製薬株式会社 | タフルプロストとクエン酸エステルとを含有するデポ剤 |
| EP4285908A3 (en) * | 2017-03-27 | 2024-02-14 | Alcon Inc. | Pharmaceutical preparation |
| US20180318319A1 (en) * | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| US11382887B2 (en) | 2017-06-22 | 2022-07-12 | Ys Life Science Co. Ltd. | Ophthalmic composition for glaucoma treatment |
| ES3041644T3 (en) * | 2017-12-21 | 2025-11-13 | Santen Pharmaceutical Co Ltd | Combination of sepetaprost and netarsudil for use in the prophylaxis or treatment of glaucoma or ocular hypertension |
| EA202190214A1 (ru) | 2018-07-09 | 2021-04-16 | Варшавске Закляды Фармацеутычне Польфа Са | Офтальмологическое дозирующее устройство |
| JP7599838B2 (ja) * | 2019-04-10 | 2024-12-16 | 参天製薬株式会社 | エピナスチン又はその塩を含有する水性医薬組成物 |
| CN111632025A (zh) * | 2020-03-04 | 2020-09-08 | 吉林大学第一医院 | 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用 |
| CN111840225B (zh) * | 2020-08-12 | 2021-09-14 | 陈丽娜 | 一种用于治疗青光眼的滴眼剂及其制备方法 |
| RU2761625C2 (ru) * | 2021-02-11 | 2021-12-13 | Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") | Фармацевтическая композиция тафлупроста |
| CN116687842A (zh) * | 2022-02-28 | 2023-09-05 | 山东新时代药业有限公司 | 一种拉坦前列素滴眼液及其制备方法 |
| JPWO2023182480A1 (enExample) * | 2022-03-25 | 2023-09-28 | ||
| CN119384280A (zh) * | 2022-06-16 | 2025-01-28 | 广州润尔眼科生物科技有限公司 | 一种药物组合物及其制备方法和应用 |
| WO2024203727A1 (ja) * | 2023-03-24 | 2024-10-03 | 株式会社坪田ラボ | 水性組成物 |
| WO2024232425A1 (ja) * | 2023-05-11 | 2024-11-14 | テイカ製薬株式会社 | プロスタグランジンＦ２α誘導体の含有率低下が抑制されている製品 |
| JP7757564B1 (ja) * | 2024-06-28 | 2025-10-21 | 東亜薬品株式会社 | 水性組成物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778815A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one |
| ES2042625T5 (es) | 1987-04-03 | 2000-07-16 | Univ Columbia | Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular. |
| US5409125A (en) | 1989-12-11 | 1995-04-25 | Aktiebolaget Astra | Unit dose container |
| DE4027320C2 (de) | 1990-08-29 | 1993-09-30 | Ursapharm Arzneimittel Gmbh | Fluid-Abgabeeinrichtung für keimfreies Fluid |
| JPH0655640A (ja) | 1992-08-04 | 1994-03-01 | Aavan Internatl:Kk | 洗面台カウンター及びその製造方法 |
| JPH06107547A (ja) | 1992-10-01 | 1994-04-19 | Aarutetsuku Ueno:Kk | 眼科用組成物 |
| AU665287B2 (en) | 1992-12-21 | 1995-12-21 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| JP2510066Y2 (ja) | 1993-01-20 | 1996-09-11 | 東洋製罐株式会社 | 加熱殺菌可能な液体医薬容器 |
| US5807892A (en) | 1994-09-30 | 1998-09-15 | Alcon Laboratories, Inc. | Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension |
| US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
| CA2237898A1 (en) * | 1995-11-17 | 1997-05-29 | Louis Desantis Jr. | Combination therapy for treating glaucoma |
| ATE221048T1 (de) | 1996-09-17 | 2002-08-15 | Asahi Glass Co Ltd | Fluorierte prostaglandinderivate und medikamente |
| JP2001505855A (ja) | 1996-12-09 | 2001-05-08 | ボシュ アンド ロム インコーポレイテッド | 使い捨て可撓容器 |
| JP3480549B2 (ja) | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
| AR002194A1 (es) | 1997-03-17 | 1998-01-07 | Sanchez Reynaldo Alemany | Instrumento computarizado para el analisis del movimiento. |
| EP0979652B1 (en) * | 1997-10-13 | 2006-05-24 | R-Tech Ueno, Ltd. | Remedial composition for intraocular hypertension or glaucoma |
| US6066671A (en) | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| GB2337740B (en) | 1998-05-26 | 2000-11-15 | Spreckelsen Mcgeough Ltd | Fluid packaging |
| BR9906597A (pt) | 1998-07-14 | 2000-07-18 | Alcon Lab Inc | Produto de prostaglandina |
| US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
| AU761785B2 (en) | 1998-09-25 | 2003-06-12 | Alcon Laboratories, Inc. | Sustained release, and comfortable ophthalmic composition and method for ocular therapy |
| US6096783A (en) | 1998-12-15 | 2000-08-01 | Alcon Laboratories, Inc. | Cyclobutane prostaglandin analogues as ocular hypotensive agents |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| EP1905757A1 (en) | 1999-04-06 | 2008-04-02 | Sepracor Inc. | Derivatives of Venlafaxine and methods of preparing and using the same |
| WO2001097852A1 (en) | 2000-06-19 | 2001-12-27 | Santen Pharmaceutical Co., Ltd. | Aseptics |
| JP3876355B2 (ja) * | 2000-09-13 | 2007-01-31 | 参天製薬株式会社 | 点眼液 |
| KR100854056B1 (ko) | 2000-09-13 | 2008-08-26 | 산텐 세이야꾸 가부시키가이샤 | 점안액 |
| TW586946B (en) | 2000-12-22 | 2004-05-11 | Novartis Ag | Process to improve stability |
| WO2004006826A1 (ja) | 2002-07-16 | 2004-01-22 | Senju Pharmaceutical Co., Ltd. | 薬液容器及びその製造方法 |
| WO2004022063A1 (ja) | 2002-09-09 | 2004-03-18 | Santen Pharmaceutical Co., Ltd. | ラタノプロストを有効成分とする澄明な点眼液 |
| US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| EP1666043B1 (en) | 2003-07-31 | 2009-12-02 | Santen Pharmaceutical Co., Ltd. | Product containing prostaglandin |
| US20050287325A1 (en) | 2004-06-25 | 2005-12-29 | Pharmacia & Upjohn Company | Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients |
| ES2314354T3 (es) * | 2004-11-09 | 2009-03-16 | Novagali Pharma S.A. | Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo. |
| US7562796B2 (en) | 2004-11-24 | 2009-07-21 | Holopack International Corp. | Dispensing container with flow control system |
| CN102526064A (zh) | 2004-12-09 | 2012-07-04 | 参天制药株式会社 | 含有分子内具有氟原子的前列腺素的制品 |
| EP1829545B1 (en) | 2004-12-24 | 2012-05-02 | Santen Pharmaceutical Co., Ltd. | Prostaglandin f2 alpha derivative containing products |
| GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
| PT1905453E (pt) | 2005-07-13 | 2012-12-04 | Santen Pharmaceutical Co Ltd | Composição conservante para utilização oftálmica |
| ES2460967T3 (es) * | 2005-08-02 | 2014-05-16 | Santen Pharmaceutical Co., Ltd. | Método para la prevención de la degradación de una sustancia térmicamente inestable |
| PT1937212E (pt) | 2005-10-10 | 2010-11-30 | Novagali Pharma Sa | Emulsões oftálmicas contendo prostaglandinas |
| FI126233B (sv) | 2006-02-23 | 2016-08-31 | Oy Kwh Mirka Ab | Oscillerande slipmaskin |
| FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| KR100927617B1 (ko) | 2007-11-26 | 2009-11-23 | 한국표준과학연구원 | 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법 |
| EP2127638A1 (en) | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
-
2008
- 2008-05-30 EP EP08397513A patent/EP2127638A1/en not_active Withdrawn
-
2009
- 2009-05-19 TW TW098116503A patent/TWI432202B/zh active
- 2009-05-27 JO JOP/2009/0192A patent/JO3039B1/ar active
- 2009-05-28 EP EP09754864.8A patent/EP2306977B1/en active Active
- 2009-05-28 BR BRPI0913109A patent/BRPI0913109B8/pt not_active IP Right Cessation
- 2009-05-28 LT LTEP20164602.3T patent/LT3714877T/lt unknown
- 2009-05-28 HR HRP20220361TT patent/HRP20220361T1/hr unknown
- 2009-05-28 JP JP2011511256A patent/JP2011521943A/ja active Pending
- 2009-05-28 DK DK20164602.3T patent/DK3714877T3/da active
- 2009-05-28 EP EP17000440.2A patent/EP3205334B1/en not_active Revoked
- 2009-05-28 EP EP20164602.3A patent/EP3714877B1/en active Active
- 2009-05-28 PL PL17000440T patent/PL3205334T3/pl unknown
- 2009-05-28 AU AU2009252210A patent/AU2009252210C1/en not_active Ceased
- 2009-05-28 DK DK14001862.3T patent/DK2772249T3/en active
- 2009-05-28 CN CN2009801197245A patent/CN102083413B/zh active Active
- 2009-05-28 KR KR1020107029072A patent/KR101650006B1/ko active Active
- 2009-05-28 SI SI200932073T patent/SI3205334T1/sl unknown
- 2009-05-28 US US12/995,351 patent/US9999593B2/en active Active
- 2009-05-28 ES ES20164602T patent/ES2907982T3/es active Active
- 2009-05-28 DK DK17000440.2T patent/DK3205334T3/da active
- 2009-05-28 DK DK09754864.8T patent/DK2306977T3/da active
- 2009-05-28 ES ES17000440T patent/ES2808050T3/es active Active
- 2009-05-28 MY MYPI2010005463A patent/MY159463A/en unknown
- 2009-05-28 PT PT140018623T patent/PT2772249T/pt unknown
- 2009-05-28 KR KR1020207014211A patent/KR102246598B1/ko active Active
- 2009-05-28 HU HUE17000440A patent/HUE049923T2/hu unknown
- 2009-05-28 KR KR1020167022210A patent/KR101820816B1/ko active Active
- 2009-05-28 ES ES09754864.8T patent/ES2495316T3/es active Active
- 2009-05-28 PT PT201646023T patent/PT3714877T/pt unknown
- 2009-05-28 SI SI200932159T patent/SI3714877T1/sl unknown
- 2009-05-28 KR KR1020187001130A patent/KR101988642B1/ko active Active
- 2009-05-28 PL PL20164602T patent/PL3714877T3/pl unknown
- 2009-05-28 EP EP21217057.5A patent/EP4035656B1/en active Active
- 2009-05-28 UA UAA201015619A patent/UA102257C2/uk unknown
- 2009-05-28 PL PL14001862T patent/PL2772249T3/pl unknown
- 2009-05-28 EP EP14001862.3A patent/EP2772249B1/en not_active Revoked
- 2009-05-28 PT PT170004402T patent/PT3205334T/pt unknown
- 2009-05-28 HR HRP20140979AT patent/HRP20140979T1/hr unknown
- 2009-05-28 EP EP23202597.3A patent/EP4289446B1/en active Active
- 2009-05-28 PL PL09754864T patent/PL2306977T3/pl unknown
- 2009-05-28 PT PT97548648T patent/PT2306977E/pt unknown
- 2009-05-28 EA EA201071413A patent/EA023661B1/ru unknown
- 2009-05-28 ES ES23202597T patent/ES3014089T3/es active Active
- 2009-05-28 ES ES14001862.3T patent/ES2627837T3/es active Active
- 2009-05-28 HU HUE20164602A patent/HUE058079T2/hu unknown
- 2009-05-28 LT LTEP14001862.3T patent/LT2772249T/lt unknown
- 2009-05-28 GE GEAP200912045A patent/GEP20156220B/en unknown
- 2009-05-28 MX MX2010012987A patent/MX2010012987A/es active IP Right Grant
- 2009-05-28 CA CA2724194A patent/CA2724194C/en active Active
- 2009-05-28 SG SG2013041751A patent/SG191628A1/en unknown
- 2009-05-28 LT LTEP17000440.2T patent/LT3205334T/lt unknown
- 2009-05-28 HU HUE14001862A patent/HUE033103T2/en unknown
- 2009-05-28 KR KR1020197016340A patent/KR102114401B1/ko active Active
- 2009-05-28 WO PCT/JP2009/060211 patent/WO2009145356A1/en not_active Ceased
- 2009-05-28 AR ARP090101912A patent/AR071937A1/es not_active Application Discontinuation
- 2009-05-28 EP EP25150453.6A patent/EP4512424A3/en active Pending
- 2009-05-28 SI SI200931050T patent/SI2306977T1/sl unknown
- 2009-05-28 ES ES21217057T patent/ES2968837T3/es active Active
- 2009-05-28 CA CA2965185A patent/CA2965185A1/en not_active Abandoned
- 2009-05-28 SI SI200931694T patent/SI2772249T1/sl unknown
-
2014
- 2014-04-22 JP JP2014088256A patent/JP2014133765A/ja active Pending
- 2014-09-18 CY CY20141100763T patent/CY1115565T1/el unknown
-
2015
- 2015-12-07 JP JP2015238594A patent/JP6148317B2/ja active Active
-
2017
- 2017-05-18 JP JP2017098843A patent/JP6356868B2/ja active Active
- 2017-05-23 HR HRP20170769TT patent/HRP20170769T1/hr unknown
- 2017-06-27 CY CY20171100675T patent/CY1120351T1/el unknown
-
2018
- 2018-06-14 JP JP2018113647A patent/JP6649992B2/ja active Active
- 2018-06-18 US US16/010,739 patent/US10864159B2/en active Active
- 2018-11-01 AR ARP180103181A patent/AR120961A2/es not_active Application Discontinuation
-
2020
- 2020-01-17 JP JP2020005799A patent/JP6889789B2/ja active Active
- 2020-06-24 HR HRP20200998TT patent/HRP20200998T1/hr unknown
- 2020-11-11 US US17/094,986 patent/US20210059931A1/en not_active Abandoned
-
2021
- 2021-05-21 JP JP2021085839A patent/JP7265584B2/ja active Active
-
2023
- 2023-04-14 JP JP2023066348A patent/JP7520285B2/ja active Active
-
2024
- 2024-04-12 JP JP2024064531A patent/JP2024079852A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071937A1 (es) | Metodo y composicion para tratar hipertension ocular y glaucoma que comprende analogos de pgf-2alfa, uso y metodo para aumentar la solubilidad acuosa y mejorar la estabilidad de los analogos de pgf-2alfa | |
| JP2016065095A5 (enExample) | ||
| ES2357551T3 (es) | Colirio. | |
| KR102675685B1 (ko) | 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물 | |
| MX2012012846A (es) | Composicion oftalmica. | |
| RU2010139958A (ru) | Стабилизированная фармацевтическая композиция, cодержащая доцетаксель | |
| RU2011146005A (ru) | Композиции для лечения воспаления и способы лечения воспаления | |
| CA2498233A1 (en) | Clear ophthalmic solution comprising latanoprost as active ingredient | |
| RU2013126259A (ru) | Фармацевтическая композиция таксоидов | |
| JP6185725B2 (ja) | 水性医薬組成物 | |
| JP5582768B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| RU2011150246A (ru) | Эмульсия "масло-в-воде" моментазона и пропиленгликоля | |
| NZ596035A (en) | METHOD AND COMPOSITION FOR TREATING MACULAR DEGENERATION using 15-keto-prostaglandin such as 13,14-dihydro-15-keto-20-ethyl-prostagladin F2-alpha isopropyl ester | |
| ES2624446T3 (es) | Compuestos donantes de óxido nítrico a base de quinona para uso oftalmológico | |
| JP2014210811A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| KR20120095341A (ko) | 라타노프로스트의 생체 이용율의 개선 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |